A human cell culture model of the lung’s most important immune cells, alveolar macrophages, helped make a key finding that is prompting researchers to rethink the role of another immune protein in infectious disease.
BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment – Pharmaceutical Technology
Tevimbra is a monoclonal antibody that targets the PD-1 receptor. Credit: rawf8 via Shutterstock. The European Commission has approved BeiGene’s PD-1 inhibitor Tevimbra (tislelizumab) in
November 27, 2024